Takeda Pharmaceutical revenue and financials

4502 · TSE · JPY

Compare Takeda Pharmaceutical
¥6,973.00Change from previous close: +0.33%Absolute change: +¥23.00

Close · November 20, 2026

In the fiscal year ended March 2026, Takeda Pharmaceutical reported revenue of ¥4.51T (−1.66% year over year). The net loss was ¥152.39B.

Annual revenue · 2026: ¥4.51T
  1. ¥1.73T2017
  2. ¥1.77T2018
  3. ¥2.1T2019
  4. ¥3.29T2020
  5. ¥3.2T2021
  6. ¥3.57T2022
  7. ¥4.03T2023
  8. ¥4.26T2024
  9. ¥4.58T2025
  10. ¥4.51T2026

Fiscal year ending in March. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
−1.66%
FY to Mar 2026 vs FY to Mar 2025
Net margin
-3.4%
FY to Mar 2025: 2.4%

How Takeda Pharmaceutical is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of JPY; per-share values in JPY; shares in millions.

Income statement · Annual
ItemFY to Mar 2026FY to Mar 2025FY to Mar 2024FY to Mar 2023FY to Mar 2022FY to Mar 2021FY to Mar 2020FY to Mar 2019FY to Mar 2018FY to Mar 2017
Total revenue4,505,7204,581,5514,263,7624,027,4783,569,0063,197,8123,291,1882,097,2241,770,5311,732,051
Cost of revenue1,619,2141,571,4191,431,5051,253,1631,127,3081,013,6551,120,146651,694495,556557,676
Gross profit2,886,5063,010,1322,832,2572,774,3152,441,6982,184,1572,171,0421,445,5301,274,9751,174,375
Selling, general and administrative1,084,1821,104,7321,053,819997,234886,327875,514964,268692,728628,106615,867
Research and development668,565730,226728,617633,325526,087455,765492,088368,257325,441311,625
Operating income607,842562,936502,602619,667600,062424,047296,680216,525177,829125,450
EBIT607,842562,936502,602619,667600,062424,047296,680216,525177,829125,450
EBITDA1,236,2741,233,2621,230,6041,284,0671,183,213983,718880,329464,216359,956296,876
Interest expense148,124130,487115,392116,973122,432130,806149,01048,15810,0367,560
Pre-tax income-142,356175,08452,791375,090302,571366,235-60,754127,612217,205143,346
Income tax9,77066,941-91,40658,05272,405-9,936-105,044-7,46830,49727,833
Net income-152,390107,928144,067317,017230,059376,00544,241135,192186,886114,940
Net income to common shareholders-152,390107,928144,067317,017230,059376,00544,241135,192186,886114,940
Basic EPS-96.7568.3692.09204.29147.14240.7228.41140.61239.35147.15
Diluted EPS-96.7567.2391.16201.94145.87238.9628.25139.82237.56146.26
Average shares (basic)1,5751,5791,5641,5521,5641,5621,557961781781
Average shares (diluted)1,5751,6051,5801,5701,5771,5741,566967787786
Dividend per share200.00196.00188.00180.00180.00180.00180.00180.00180.00180.00

Companies in the group: same industry, similar size